
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1399712/publications.pdf Version: 2024-02-01



LAURA ROIKE

#	Article	IF	CITATIONS
1	Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment. Pharmacoeconomics, 2006, 24, 355-371.	3.3	390
2	The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease – a UK collaborative study. The REFLUX trial. Health Technology Assessment, 2008, 12, 1-181, iii-iv.	2.8	319
3	Characterizing Structural Uncertainty in Decision Analytic Models: A Review and Application of Methods. Value in Health, 2009, 12, 739-749.	0.3	123
4	Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Health Technology Assessment, 2006, 10, 1-132. iii-iv.	2.8	97
5	Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment, 2011, 15, i-xxi, 1-329.	2.8	84
6	A Framework for Addressing Structural Uncertainty in Decision Models. Medical Decision Making, 2011, 31, 662-674.	2.4	72
7	Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses. Health Technology Assessment, 2007, 11, 1-226, iii.	2.8	64
8	Designing and Undertaking a Health Economics Study of Digital Health Interventions. American Journal of Preventive Medicine, 2016, 51, 852-860.	3.0	60
9	Eliciting Distributions to Populate Decision Analytic Models. Value in Health, 2010, 13, 557-564.	0.3	47
10	Methods to elicit experts' beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration. Statistics in Medicine, 2011, 30, 2363-2380.	1.6	47
11	A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions. Value in Health, 2016, 19, 885-891.	0.3	38
12	Methods to Assess Cost-Effectiveness and Value of Further Research When Data Are Sparse. Medical Decision Making, 2013, 33, 415-436.	2.4	32
13	Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses. Value in Health, 2018, 21, 715-723.	0.3	31
14	Improving cardiac rehabilitation uptake: Potential health gains by socioeconomic status. European Journal of Preventive Cardiology, 2019, 26, 1816-1823.	1.8	29
15	Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study. Health Technology Assessment, 2021, 25, 1-124.	2.8	29
16	A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic) Tj ETQq0 0 0 rgBT /Overle	ock 10 Tf 5	50 142 Td (Fu 26

17	Identifying Research Priorities: The Value of Information Associated with Repeat Screening for Age-Related Macular Degeneration. Medical Decision Making, 2008, 28, 33-43.	2.4	25
18	Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology, 2011, 50, iv39-iv47.	1.9	24

#	Article	IF	CITATIONS
19	Informing Reimbursement Decisions Using Cost-Effectiveness Modelling: A Guide to the Process of Generating Elicited Priors to Capture Model Uncertainties. Pharmacoeconomics, 2017, 35, 867-877.	3.3	22
20	Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technology Assessment, 2017, 21, 1-326.	2.8	21
21	Capturing all of the costs in NICE appraisals: the impact of inflammatory rheumatic diseases on productivity. Rheumatology, 2012, 51, 210-215.	1.9	18
22	Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required. Value in Health, 2015, 18, 865-875.	0.3	17
23	Belief Elicitation to Populate Health Economic Models of Medical Diagnostic Devices in Development. Applied Health Economics and Health Policy, 2014, 12, 327-334.	2.1	16
24	Systematic Review and Critique of Methods for Economic Evaluation of Digital Mental Health Interventions. Applied Health Economics and Health Policy, 2021, 19, 17-27.	2.1	15
25	How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis. Pharmacoeconomics, 2017, 35, 767-776.	3.3	14
26	Model Structuring for Economic Evaluations of New Health Technologies. Pharmacoeconomics, 2018, 36, 1309-1319.	3.3	13
27	A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study. BMJ Open, 2016, 6, e010686.	1.9	12
28	Economic Evaluation of Environmental Interventions: Reflections on Methodological Challenges and Developments. International Journal of Environmental Research and Public Health, 2018, 15, 2459.	2.6	12
29	Reference Case Methods for Expert Elicitation in Health Care Decision Making. Medical Decision Making, 2022, 42, 182-193.	2.4	12
30	Digital interventions in mental health: evidence syntheses and economic modelling. Health Technology Assessment, 2022, 26, 1-182.	2.8	12
31	Using Cost-Effectiveness Analysis to Quantify the Value of Genomic-Based Diagnostic Tests: Recommendations for Practice and Research. Genetic Testing and Molecular Biomarkers, 2017, 21, 705-716.	0.7	11
32	The cost-effectiveness of population Health Checks: have the NHS Health Checks been unfairly maligned?. Zeitschrift Fur Gesundheitswissenschaften, 2017, 25, 425-431.	1.6	11
33	Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party. Rheumatology and Therapy, 2015, 2, 113-125.	2.3	10
34	Estimating the health loss due to poor engagement with cardiac rehabilitation in Australia. International Journal of Cardiology, 2020, 317, 7-12.	1.7	10
35	The Cost Effectiveness of Ecotherapy as a Healthcare Intervention, Separating the Wood from the Trees. International Journal of Environmental Research and Public Health, 2021, 18, 11599.	2.6	10
36	Digital Interventions for Generalized Anxiety Disorder (GAD): Systematic Review and Network Meta-Analysis. Frontiers in Psychiatry, 2021, 12, 726222.	2.6	10

#	Article	IF	CITATIONS
37	A discrete choice experiment to explore patients' willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis. Clinical Rheumatology, 2016, 35, 2967-2974.	2.2	9
38	Impact of specialist rehabilitation services on hospital length of stay and associated costs. European Journal of Health Economics, 2018, 19, 1027-1034.	2.8	8
39	Quantifying the impact of delayed delivery of cardiac rehabilitation on patients' health. European Journal of Preventive Cardiology, 2020, 27, 1775-1781.	1.8	8
40	Antimicrobial-impregnated central venous catheters for preventing neonatal bloodstream infection: the PREVAIL RCT. Health Technology Assessment, 2020, 24, 1-190.	2.8	8
41	Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease. PharmacoEconomics - Open, 2018, 2, 403-413.	1.8	7
42	The Relevant Perspective of Economic Evaluations Informing Local Decision Makers: An Exploration in Weight Loss Services. Applied Health Economics and Health Policy, 2020, 18, 351-356.	2.1	6
43	Modelling the impact of physical activity on public health: A review and critique. Health Policy, 2020, 124, 1155-1164.	3.0	6
44	Model to Determine the Costâ€Effectiveness of Screening Psoriasis Patients for Psoriatic Arthritis. Arthritis Care and Research, 2021, 73, 266-274.	3.4	6
45	Cost Effectiveness of Increasing the Dose Intensity of Chemotherapy with Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer. Pharmacoeconomics, 2006, 24, 443-452.	3.3	5
46	Improving Decision-Making Processes in Health: Is It Time for (Disease-Specific) Reference Models?. Applied Health Economics and Health Policy, 2020, 18, 1-4.	2.1	5
47	Cost-effectiveness of strategies preventing late-onset infection in preterm infants. Archives of Disease in Childhood, 2020, 105, 452-457.	1.9	5
48	Cost-effectiveness of a proportionate universal offer of free exercise: Leeds Let's Get Active. Journal of Public Health, 2021, 43, 876-886.	1.8	4
49	Delayed transfers of care for older people: a wider perspective. Age and Ageing, 2021, 50, 1073-1076.	1.6	4
50	Golimumab for the treatment of psoriatic arthritis. Health Technology Assessment, 2011, 15, 87-96.	2.8	4
51	Cost Effectiveness of Digital Interventions for Generalised Anxiety Disorder: A Model-Based Analysis. PharmacoEconomics - Open, 2022, 6, 377-388.	1.8	4
52	Modelling decay in effectiveness for evaluation of behaviour change interventions: a tutorial for public health economists. European Journal of Health Economics, 2022, 23, 1151-1157.	2.8	3
53	The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence. Pharmacoeconomics, 2016, 34, 1101-1110.	3.3	2
54	Work Disability and the Cost-effectiveness of Drugs to Treat Rheumatic Diseases — Time for a New Dialogue?. Journal of Rheumatology, 2018, 45, 1075-1077.	2.0	2

#	Article	IF	CITATIONS
55	Taking a local government perspective for economic evaluation of a population-level programme to promote exercise. Health Policy, 2021, 125, 651-657.	3.0	2
56	Does providing everyone with free-of-charge organised exercise opportunities work in public health?. Health Policy, 2022, 126, 129-142.	3.0	2
57	Understanding and addressing the challenges of conducting quantitative evaluation at a local level: a worked example of the available approaches. BMJ Open, 2019, 9, e029830.	1.9	1
58	Eliciting uncertainty for complex parameters in model-based economic evaluations: quantifying a temporal change in the treatment effect. International Journal of Technology Assessment in Health Care, 2022, 38, e21.	0.5	1
59	Linee guida di buona pratica per creare modelli analitico-decisionali nella valutazione delle tecnologie sanitarie. Giornale Italiano Di Health Technology Assessment, 2008, 1, 1-14.	0.1	0
60	Golimumab per il trattamento dell'artrite psoriasica. Pharmacoeconomics Italian Research Articles, 2013, 15, 131-141.	0.2	0
61	Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?. Clinical Rheumatology, 2017, 36, 1803-1810.	2.2	0